Financing ·
BioLineRx reported Q2 2026 net loss of $4.3 million, driven by a $0.6 million increase in R&D expenses for GLIX1 and a…
BLRXBioLineRx Ltd.
BioLineRx reported Q2 2026 net loss of $4.3 million, driven by a $0.6 million increase in R&D expenses for GLIX1 and a $0.7 million rise in G&A due to a prior-year doubtful account reversal. The company holds $13.1 million in cash as of June 30, 2026, maintaining its runway into the first half of 2027. On August 27, 2026, BioLineRx entered a definitive agreement for an offering with gross proceeds of $3.75 million, expected to close on or about August 31, 2026. Clinically, GLIX1 dosing commenced in the second cohort of its Phase 1/2a glioblastoma trial, with the third cohort expected in September. Preclinical data showed potent anti-tumor activity in TMZ-resistant GBM models and strong synergy between GLIX1 and PARP inhibitors in ovarian cancer models, prompting plans to add an ovarian cancer arm to the Phase 2a expansion. BioLineRx is a clinical-stage biopharmaceutical company developing oncology therapies including GLIX1 for glioblastoma and motixafortide.